Скачать или смотреть CHEAP Dividend Stock to BUY...NOW?!? | $68 BILLION Pharma Completes SPIN-OFF AND Consolidates Shares

This big pharma stock could be a great, cheap dividend stock to buy now. After completing a spin-off, consolidating shares and getting out of a legal suit, this pharmaceutical could be set up for future success. The future success could be set up for significant dividend growth.

Why do dividends matter? Dividends are one of the best passive income sources. Dividend investing increases your passive income, as you reach financial freedom!

Reference items:
►Fundrise - Dividend Diplomats Use this for Real Estate Investing: https://fundrise.sjv.io/9aJWW
►Dividend Diplomats Stock Portfolios: https://www.dividenddiplomats.com/our...
►Dividend Diplomats Blog: https://www.dividenddiplomats.com/

There were THREE big events that occurred on this pharmaceutical stock. The three events coudl lead to showing more promise for this dividend growth stock - for both strong dividend growth going forward and possible appreciation of the stock price.

First, this dividend stock spun-off it's consumer brand division. This is so the healthcare company can focus on strictly Bio-pharma, such as medicines and vaccines. This is following suit with Pfizer and then with Johnson & Johnson, upcoming in 2023. The newly created company of discussion holds brands such as Aquafresh, Advil and dozens of others.

Second, the dividend growth stock also performed a stock consolidation. For every 5 shares of this stock, this was shrunk down to 4 shares. Example: if you owned 100 shares, your position actually was reduced down to 80 shares or 80% of the quantity of shares outstanding.

Third is the legal battle. Yes, there are thousands of claims against the use of Zantac, which has been pulled from U.S. shelves, due to risk of cancer. The company of discussion is continuing to fight the claims and now - this battle falls within the newly created company - Haleon (HLN).

We are talking about GlaxoSmithKline or GSK. This stock has had quite a volatile last few years, especially in regards to their stock price. However, now that these 3 big items are completed and they are able to focus on Bio-pharma, is it time for further value and dividend growth for this cheap stock?

This could be a great stock to buy now, as we ran them through the Dividend diplomat Stock Screener, which is focused on 3 dividend growth metrics:
1.) Price to Earnings Ratio less than S&P 500
2.) Payout Ratio less than 60%
3.) A history of growing their dividend

Glasko definitely has a low price to earnings ratio, at approximately 10x forward earnings. In addition, the dividend is fairly safe, as the ratio stands at 46%. However, it is hard to gauge where we are at on the dividend growth front and with the 3 massive events that occurred in the last 60 days, may be some time until we know the full features of the dividend for GSK. However, it is worthy to note, that management is aiming for a 40-60% payout ratio, which is the exact same payout ratio we like to see!

We shall see if I buy more shares of this dividend stock. Are you considering buying GSK stock? Do you think this is a dividend stock to buy right now? Are you going to pass on this big Pharma stock because you think Pfizer and AbbVie or Johnson & Johnson is better? What other stocks are you watching right now? Definitely let us know in the comments.

Thank you everyone! Subscribe, like and let us know your feedback & questions below!

Follow us on:
►Twitter:   / dvdnddiplomats  
►Instagram:   / dividenddiplomats  

As always, we recommend conducting your own research to make your own decisions.

#dividends #stocks #stockstobuy #stockstobuytoday #passiveincome #income